Bad news from the Novo Nordisk A/S phase III trial called Zeus with IL-6 inhibitor ziltivekimab struck a blow to some drug developers’ theory about heart disease – and to their stocks. An update on ...

Scientists in the U.K. have used genome mining to identify bacterial species capable of producing novel polyene antifungal compounds that are both more effective and have a more benign side effect ...

The hot in vivo CAR T therapy space bubbled with news again as Johnson & Johnson (J&J) apparently forsook partner Legend Biotech Corp. and tapped Sail Biomedicines Inc. for a collaboration that will ...

Med-tech deal value, covering licensing agreements, joint ventures and development collaborations, through the first half (H1) of 2026 reached $5.28 billion, the second-highest H1 total behind 2023’s ...

CAR T-cell therapy has been highly effective in hematologic cancers but faces challenges in solid tumors due to the lack of safe, uniformly expressed surface antigens. A recent study found that the ...

Elix Inc. and the University of Vienna have signed a joint research agreement aimed at advancing drug discovery using AI technologies.

The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how regulators should oversee ...

Sail Biomedicines Inc. has established a strategic collaboration with Johnson & Johnson (J&J) to advance innovative in vivo CAR T therapies for immune-mediated diseases.

Shanghai Qilu Pharmaceutical Research Development Centre Ltd. has identified soluble guanylate cyclase (sGC) activators that are potentially useful for the treatment of chronic kidney disease and ...

Abcellera Biologics Inc. has established a collaboration with Vertex Pharmaceuticals Inc. to research, develop, manufacture and commercialize multispecific T-cell engagers (TCEs) for autoimmune ...

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Abbvie, Allogene, Amgen, Eton, Hopstem, Incyte, Insilico, ...

Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and disease.